MONTREAL, November 16, 2019 / CNW / – The Montreal Heart Institute (MHI) today announced the results of its COLchicine Cardiovascular Outcomes Study (COLCOT). This landmark study compared the effect of colchicine on preventing ischemic cardiovascular events in patients with a recent myocardial infarction (MI) receiving the standard of care. In this study, patients receiving colchicine 0.5 mg daily, in addition to standard of care, had a lower rate of recurrent and recurrent ischemic cardiovascular events compared with patients receiving standard treatment alone. These data were published simultaneously in the New England Journal of Medicine (NEJM) and were presented today at a scientific session of the American Heart Association (AHA).
Pharmascience Inc. is proud to have contributed to this groundbreaking clinical trial, the results of which can have major positive impacts on patients' cardiovascular outcomes and overall public health. Inflammation has been shown to play an important role in cardiovascular disease, and COLCOT results represent a very significant advance in linking the reduction of post-myocardial infarction inflammation to better cardiovascular outcomes.
An important aspect of the COLCOT study is that it allows the redirection of colchicine, a drug used for decades in the treatment of familial Mediterranean gout or fever. Reusing older and more established drugs involves discovering additional uses for already approved drugs.
"Pharmascience has made the decision to support healthcare innovations like COLCOT, here in Canada. Our goal is to support therapeutic innovation and improve patient outcomes with a new indication for an old and reliable drug that can be offered at an affordable cost, "he said. David Goodman, Ph.D., CEO of Pharmascience, "We believe these projects are perfectly suited to our desire to contribute to therapeutic advances through responsible entrepreneurship."
The clinical use of colchicine is supported by a well-known safety profile and is available at a very affordable cost compared to some newer cardiovascular medicines used in similar indications. Reused generic drugs offer attractive and cost-effective options for public and private drug reimbursement programs in their constant struggle against accessibility challenges when it comes to new drugs.
"Unfortunately, few pharmaceutical manufacturers venture down this path because of inherent trade barriers," Dr. Goodman added, "There is no guarantee that the additional R&D investments required for drug reuse will be recovered due to lack of intellectual property protection typically found with generic drugs Pharmascience is willing to take that risk for the greater good, but we will need the assistance of drug program regulators and managers to put in place approval and reimbursement structures that do not discourage reuse. medicines and reward innovation ".
ABOUT PHARMASCIENCE INC.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly based in Montreal. Pharmascience Inc. is a full service private pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. 56th ranked among From Canada Top 100 Research and Development (R&D) investors with more than $ 43 million Invested in 2018, Pharmascience Inc. is the fourth largest generic drug manufacturer in the country.
Pharmascience Inc. has strong values based on the importance of investing in its employees and youth. Through various programs and initiatives, the company ensures that it supports development and personal life. In 2019, Pharmascience Inc. was proudly recognized for its investments by being selected as one of the From Canada Top Employers for Youth and appointed one of the Montreal's best employers as part of the From Canada Top 100 Employers Project. In 2018, the prestigious Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers.
SOURCE Pharmascience Inc.
For More Information: Media Information: Andrea Frascione, Communications Manager, Tel: 514-796-4067